《Insight Partners：2024-2030年歐洲基因檢測服務市場分析與預測報告（英文版）（104頁）.pdf》由會員分享，可在線閱讀，更多相關《Insight Partners：2024-2030年歐洲基因檢測服務市場分析與預測報告（英文版）（104頁）.pdf（104頁珍藏版）》請在三個皮匠報告上搜索。

1、 Europe Genetic Testing Services Market Market Size and Forecast(2020-2030)Regional Growth Opportunity Analysis Coverage:By Service Service TypeType(Predictive Testing,Carrier Testing,Prenatal Testing,Newborn Screening,and Others),DiseaseDisease(Cancer,Metabolic Diseases,Cardiovascular Diseases,and

2、Other Diseases),Service Service ProviderProvider(Hospital-Based Laboratories,Diagnostic Laboratories,and Others),and CountryCountry 2 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Table of Content 1.Introduction.14 1.1 The Insight Partners Research Report Guidance.14 1.2 Mar

3、ket Segmentation.15 2.Executive Summary.16 2.1 Key Insights.16 3.Research Methodology.17 3.1 Coverage.18 3.2 Secondary Research.18 3.3 Primary Research.18 4.Europe Genetic Testing Services Market-Key Industry Dynamics.20 4.1 Key Market Drivers.20 4.1.1 Rising Prevalence of Genetic Diseases.20 4.1.2

4、Increasing Awareness and Acceptance of Personalized Medicines.21 4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing.21 4.2 Market Restraints.22 4.2.1 Social and Ethical Implications of Genetic Testing.22 4.2.2 Affordability of Genetic Services.22 4.3 Market Opportunities.23 4.3.1 Ri

5、sing Demand for Pharmacogenomics.23 4.4 Future Trends.23 4.4.1 Artificial Intelligence-Powered Genetic Testing.23 4.5 Impact Analysis:.24 5.Genetic Testing Services Market-Europe Market Analysis.25 5.1 Europe Genetic Testing Services Market Revenue(US$Mn),2022 2030.25 6.Europe Genetic Testing Servic

6、es Market Revenue and Forecast to 2030 by Service Type.26 6.1 Overview.26 6.2 Europe Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).26 6.3 Predictive Testing.27 6.3.1 Overview.27 3 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3.2 Predictive Tes

7、ting:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 6.4 Carrier Testing.28 6.4.1 Overview.28 6.4.2 Carrier Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 6.5 Prenatal Testing.29 6.5.1 Overview.29 6.5.2 Prenatal Testing:E

8、urope Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 6.6 Newborn Screening.30 6.6.1 Overview.30 6.6.2 Newborn Screening:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).30 6.7 Others.31 6.7.1 Overview.31 6.7.2 Others:Europe Genetic Testing

9、Services Market Revenue and Forecast to 2030(US$Million).31 7.Europe Genetic Testing Services Market Revenue and Forecast to 2030 by Disease.33 7.1 Overview.33 7.2 Europe Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).33 7.3 Cancer.34 7.3.1 Overview.34 7.3.2 Cancer:Europe Gene

10、tic Testing Services Market Revenue and Forecast to 2030(US$Million).34 7.4 Cardiovascular Diseases.35 7.4.1 Overview.35 7.4.2 Cardiovascular Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 7.5 Metabolic Diseases.36 7.5.1 Overview.36 7.5.2 Metabolic Diseas

11、es:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).36 7.6 Other Diseases.37 7.6.1 Overview.37 7.6.2 Other Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).37 4 Europe Genetic Testing Services Market,2020-2030 |The Insight Partne

12、rs 8.Europe Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider.39 8.1 Overview.39 8.2 Europe Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).39 8.3 Hospital-Based Laboratories.40 8.3.1 Overview.40 8.3.2 Hospital-Based Laboratories:Europe G

13、enetic Testing Services Market Revenue and Forecast to 2030(US$Million).40 8.4 Diagnostic Laboratories.41 8.4.1 Overview.41 8.4.2 Diagnostic Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).41 8.5 Others.42 8.5.1 Overview.42 8.5.2 Others:Europe Genetic Tes

14、ting Services Market Revenue and Forecast to 2030(US$Million).42 9.Europe Genetic Testing Services Market-Country Analysis.43 9.1 Europe.43 9.1.1 Europe Genetic Testing Services Market,by Country.43 9.1.1.1 UK.44 9.1.1.1.1 Overview.44 9.1.1.1.2 UK Genetic Testing Services Market Revenue and Forecast

15、 to 2030(US$Mn).44 9.1.1.1.3 UK Genetic Testing Services Market,by Service Type,20202030(US$Million).45 9.1.1.1.4 UK Genetic Testing Services Market,by Disease,20202030(US$Million).45 9.1.1.1.5 UK Genetic Testing Services Market,by Service Provider,20202030(US$Million).45 9.1.1.2 Germany.46 9.1.1.2.

16、1 Overview.46 9.1.1.2.2 Germany:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).46 9.1.1.2.3 Germany:Europe Genetic Testing Services Market,by Service Type,20202030(US$Million).47 9.1.1.2.4 Germany:Europe Genetic Testing Services Market,by Disease,20202030(US$Million).48 9

17、.1.1.2.5 Germany:Europe Genetic Testing Services Market,by Service Provider,20202030(US$Million).48 9.1.1.3 France.49 5 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.1 Overview.49 9.1.1.3.2 France Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).49

18、 9.1.1.3.3 France Genetic Testing Services Market,by Service Type,20202030(US$Million).50 9.1.1.3.4 France Genetic Testing Services Market,by Disease,20202030(US$Million).51 9.1.1.3.5 France Genetic Testing Services Market,by Service Provider,20202030(US$Million).51 9.1.1.4 Italy.52 9.1.1.4.1 Overvi

19、ew.52 9.1.1.4.2 Italy Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).52 9.1.1.4.3 Italy Genetic Testing Services Market,by Service Type,20202030(US$Million).53 9.1.1.4.4 Italy Genetic Testing Services Market,by Disease,20202030(US$Million).53 9.1.1.4.5 Italy Genetic Testing Serv

20、ices Market,by Service Provider,20202030(US$Million).53 9.1.1.5 Spain.54 9.1.1.5.1 Overview.54 9.1.1.5.2 Spain Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).54 9.1.1.5.3 Spain Genetic Testing Services Market,by Service Type,20202030(US$Million).55 9.1.1.5.4 Spain Genetic Testin

21、g Services Market,by Disease,20202030(US$Million).55 9.1.1.5.5 Spain Genetic Testing Services Market,by Service Provider,20202030(US$Million).55 9.1.1.6 Rest of Europe.56 9.1.1.6.1 Overview.56 9.1.1.6.2 Rest of Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).56 9.1.1.6.3 R

22、est of Europe Genetic Testing Services Market,by Service Type,20202030(US$Million).57 9.1.1.6.4 Rest of Europe Genetic Testing Services Market,by Disease,20202030(US$Million).57 9.1.1.6.5 Rest of Europe Genetic Testing Services Market,by Service Provider,20202030(US$Million).58 10.Genetic Testing Se

23、rvices MarketIndustry Landscape.59 10.1 Overview.59 10.2 Growth Strategies in Genetic Testing Services Market.59 6 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 10.3 Organic Growth Strategies.60 10.3.1 Overview.60 10.4 Inorganic Growth Strategies.62 10.4.1 Overview.62 11.Com

24、pany Profiles.63 11.1 Eurofins Scientific SE.63 11.1.1 Key Facts.63 11.1.2 Business Description.63 11.1.3 Products and Services.64 11.1.4 Financial Overview.65 11.1.5 SWOT Analysis.66 11.1.6 Key Developments.67 11.2 Exact Sciences Corp.68 11.2.1 Key Facts.68 11.2.2 Business Description.68 11.2.3 Pro

25、ducts and Services.68 11.2.4 Financial Overview.69 11.2.5 SWOT Analysis.70 11.2.6 Key Developments.71 11.3 Laboratory Corp of America Holdings.72 11.3.1 Key Facts.72 11.3.2 Business Description.72 11.3.3 Products and Services.72 11.3.4 Financial Overview.73 11.3.5 SWOT Analysis.74 11.3.6 Key Develop

26、ments.75 11.4 23andMe Holding Co.76 11.4.1 Key Facts.76 11.4.2 Business Description.76 11.4.3 Products and Services.77 11.4.4 Financial Overview.77 11.4.5 SWOT Analysis.78 11.4.6 Key Developments.79 11.5 Quest Diagnostics Inc.80 11.5.1 Key Facts.80 7 Europe Genetic Testing Services Market,2020-2030

27、|The Insight Partners 11.5.2 Business Description.80 11.5.3 Products and Services.81 11.5.4 Financial Overview.81 11.5.5 SWOT Analysis.82 11.5.6 Key Developments.83 11.6 Illumina Inc.84 11.6.1 Key Facts.84 11.6.2 Business Description.84 11.6.3 Products and Services.85 11.6.4 Financial Overview.85 11

28、.6.5 SWOT Analysis.86 11.6.6 Key Developments.87 11.7 F.Hoffmann-La Roche Ltd.88 11.7.1 Key Facts.88 11.7.2 Business Description.88 11.7.3 Products and Services.89 11.7.4 Financial Overview.89 11.7.5 SWOT Analysis.91 11.7.6 Key Developments.93 11.8 NeoGenomics Inc.94 11.8.1 Key Facts.94 11.8.2 Busin

29、ess Description.94 11.8.3 Products and Services.94 11.8.4 Financial Overview.95 11.8.5 SWOT Analysis.96 11.8.6 Key Developments.97 11.9 Centogene AG.98 11.9.1 Key Facts.98 11.9.2 Business Description.98 11.9.3 Products and Services.98 11.9.4 Financial Overview.99 11.9.5 SWOT Analysis.100 11.9.6 Key

30、Developments.101 12.Appendix.102 12.1 About Us.102 8 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 12.2 Glossary of Terms.103 9 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners List of Tables Table 1.Europe Genetic Testing Services Market Segmentation.1

31、5 Table 2.UK Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).45 Table 3.UK Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).45 Table 4.UK Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Mi

32、llion).45 Table 5.Germany:Europe Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).47 Table 6.Germany:Europe Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).48 Table 7.Germany:Europe Genetic Testing Services Market,by Service

33、 Provider Revenue and Forecast to 2030(US$Million).48 Table 8.France Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).50 Table 9.France Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).51 Table 10.France Genetic Testing Servi

34、ces Market,by Service Provider Revenue and Forecast to 2030(US$Million).51 Table 11.Italy Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).53 Table 12.Italy Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).53 Table 13.Italy G

35、enetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).53 Table 14.Spain Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).55 Table 15.Spain Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)

36、.55 Table 16.Spain Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).55 Table 17.Rest of Europe Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).57 10 Europe Genetic Testing Services Market,2020-2030 |The Insight Part

37、ners Table 18.Rest of Europe Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).57 Table 19.Rest of Europe Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).58 Table 20.Recent Organic Growth Strategies in Europe Genetic Test

38、ing Services Market.60 Table 21.Recent Inorganic Growth Strategies in the Europe Genetic Testing Services Market.62 Table 22.Glossary of Terms,Europe Genetic Testing Services Market.103 11 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners List of Figures Figure 1.Europe Genetic

39、Testing Services Market Segmentation,By Country.15 Figure 2.Europe Genetic Testing Services Market-Key Industry Dynamics.20 Figure 3.Impact Analysis of Drivers and Restraints.24 Figure 4.Europe Genetic Testing Services Market Revenue(US$Mn),2022 2030.25 Figure 5.Europe Genetic Testing Services Marke

40、t Revenue Share,by Service Type,2022&2030(%).26 Figure 6.Predictive Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).27 Figure 7.Carrier Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 Figure 8.Prenatal Testing:Europe

41、Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 Figure 9.Newborn Screening:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).30 Figure 10.Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).32 Figure 11.Euro

42、pe Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%).33 Figure 12.Cancer:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).34 Figure 13.Cardiovascular Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 Figure

43、14.Metabolic Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).36 Figure 15.Other Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).38 Figure 16.Europe Genetic Testing Services Market Revenue Share,by Service Provider,2022

44、&2030(%).39 Figure 17.Hospital-Based Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).40 Figure 18.Diagnostic Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).41 Figure 19.Others:Europe Genetic Testing Services M

45、arket Revenue and Forecast to 2030(US$Million).42 12 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 20.Europe Genetic Testing Services Market,by Key Country Revenue,2022(US$Million).43 Figure 21.Europe Genetic Testing Services Market,By Key Countries,2022 and 2030(%).4

46、3 Figure 22.UK Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).44 Figure 23.Germany:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).47 Figure 24.France Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).50 Figure 25.Italy Genetic Testin

47、g Services Market Revenue and Forecast to 2030(US$Mn).52 Figure 26.Spain Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).54 Figure 27.Rest of Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).56 Figure 28.Growth Strategies in Genetic Testing Services Mark

48、et.59 13 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners NOTES:The list of companies included in the scope are as per standard report format and the list can be modified/expanded as per clients requirement The sequence/list of companies do not represent their current position

49、in the market.The list of countries provided in the report are part of standard report and can be customized as per clients requirement RELATED REPORTS Newborn Genetic Testing Market DTC Genetic Testing Market 14 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 1.Introduction 1

50、.1 The Insight Partners Research Report Guidance The report provides qualitative and quantitative trends of Europe genetic testing services market across service type,disease,service provider,and country.The report starts with the key takeaways(chapter 2),highlighting the key trends and outlook of t

51、he Europe genetic testing services market.Chapter 3 provides the research methodology of the study.Chapter 4 highlights the key industry dynamics in the Europe genetic testing services market,including factors that are driving the market,prevailing deterrent,potential opportunities as well as future

52、 trends.Impact analysis of these drivers and restraints is also covered in this section.Chapter 5 discusses the Europe genetic testing services market scenario,in terms of historical market revenues,and forecast till 2030.Chapter 6 to 9 discuss genetic testing services market segments by service typ

53、e,disease,service provider,and countries across Europe.They cover market revenue forecast,and factors driving and governing growth.Chapter 10 describes the industry landscape analysis.It provides detailed description of various business activities such as market initiatives,new developments,mergers,

54、and joint ventures globally along with a competitive landscape.Chapter 11 provides the detailed profiles of the key companies operating in the Europe genetic testing services market.The companies have been profiled on the basis of their key facts,business description,products and services,financial

55、overview,SWOT analysis,and key developments.Chapter 12,i.e.the appendix is inclusive of a brief overview of the company,glossary of terms,contact information,and the disclaimer section.15 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 1.2 Market Segmentation Table 1.Europe Ge

56、netic Testing Services Market Segmentation SERVICE TYPESERVICE TYPE DISEASEDISEASE SERVICE SERVICE PROVIDERPROVIDER PREDICTIVE TESTING CANCER HOSPITAL-BASED LABORATORIES CARRIER TESTING CARDIOVASCULAR DISEASES DIAGNOSTIC LABORATORIES PRENATAL TESTING METABOLIC DISEASES OTHERS NEWBORN SCREENING OTHER

57、 DISEASES OTHERS Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Figure 1.Europe Genetic Testing Services Market Segmentation,By Country Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The Europe geneti

58、c testing services market is segmented based on service type,disease,service provider,and country.The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research.In addition,the market is also segmented on the basis of services offered by th

59、e leading participants in the industry in order to understand widely used market specific terminologies.Thus,we have incorporated the segments of the research and have finalized the market segmentation.EUROPEFRANCE GERMANY UK SPAINITALY RoE 16 Europe Genetic Testing Services Market,2020-2030 |The In

60、sight Partners 2.Executive Summary 2.1 Key Insights OverviewMarket SegmentationMarket DynamicsRegional OverviewMarket SegmentationKey PlayersMarket DynamicsCAGR(2022-2030)14.6%Market Size 2022$931.11MnMarket Size 2030$2,778.42MnService TypeDisease Predictive Testing Carrier Testing Prenatal Testing

61、Newborn Screening Others Cancer Cardiovascular Diseases Metabolic Diseases Other Diseases Laboratory Corporation of America Holdings F.Hoffmann-La Roche Ltd Illumina,Inc.Quest Diagnostics Incorporated Exact Sciences Corp(Genomic Health)NeoGenomics Laboratories,Inc.Eurofins Scientific Centogene AG 23

62、andMe,IncGROWTH DRIVERSFUTURE TRENDSGROWTH DRIVERSFUTURE TRENDS Rising Prevalence of Genetic Diseases Increasing Awareness and Acceptance of Personalized Medicines Artificial Intelligence-Powered Genetic TestingRESTRAINTSOPPORTUNITY Social and Ethical Implications of Genetic Testing Affordability of

63、 Genetic Services Untapped Emerging Markets in Developing CountriesService Provider Hospital-Based Laboratories Diagnostic Laboratories OthersEUROPE14.6%17 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 3.Research Methodology The Insight Partners dedicated research and analys

64、is team consist of experienced professionals with advanced statistical expertise in market research and consulting backgrounds in in various industries including Aerospace and Defense,Automotive and Transportation,Biotechnology,Chemicals and Materials,Food and Beverages,Electronics and Semiconductor

65、,Healthcare IT,Manufacturing and Construction,Medical Device,Technology,Media and Telecommunications.Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources FinalMarket sizeValidation from Primary InterviewSummation of Revenue Generated from Companies to arri

66、ve Total Market SizeRevenue Generated by the Products and Services Offered by Companies in the Genetic Testing Service MarketFinal Market Size Break-Up To Rest Of Segmentation(i.e.,Service Type,Disease,Service Provider,and Region)Arriving at the Market Size of each Segment Validation of Number with

67、Primary Interviews and Subject Matter Expert BOTTOM-UP ANALYSISTOP-DOWN ANALYSIS 18 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners The Insight Partners adheres to the codes of practice of the Market Research Society(www.mrs.org.uk)and Strategic and Competitive Intelligence Pr

68、ofessionals(www.scip.org).The following methodology has been followed for the collection and analysis of data presented in this report:3.1 Coverage The objective of updating“The Insight Partners”coverage is to ensure that it represents the most up-to-date vision of the industry possible.The estimate

69、d revenues of all major companies,including private and governmental,are gathered and used to prioritize coverage.Companies which are making the news,or which are of particular interest due to their innovative approach,are prioritized.3.2 Secondary Research The research process begins with exhaustiv

70、e secondary research using internal and external sources to obtain qualitative and quantitative information relating to each Market.The secondary research sources that are typically referred to include,but are not limited to:Company websites,annual reports,financial reports,broker reports and invest

71、or presentations Industry trade journals and other literature National government documents,statistical databases and market reports News articles,press releases and web-casts specific to the companies operating in the market NOTE:All the financials considered in Company Profiles section have been s

72、tandardized to US$.This has been achieved after converting the financials(for those not in US$)with respective currency exchange rates of the particular year.3.3 Primary Research“The Insight Partners”conducts hundreds of primary interviews a year with industry participants and commentators in order

73、to validate its data and analysis.A typical research interview fulfils the following functions:Provides first-hand information on the market size,market trends,growth trends,competitive landscape and future outlook Validates and strengthens secondary research findings Further develops the analysis t

74、eams expertise and market understanding 19 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Primary research involves email interactions and telephone interviews for each market,category,segment and sub-segment across countries.The participants who typically take part in such a

75、 process include,but are not limited to:Industry participants:VPs,business development managers,market intelligence managers and national sales managers Outside experts:Valuation experts,research analysts and key opinion leaders specializing in the industry 20 Europe Genetic Testing Services Market,

76、2020-2030 |The Insight Partners 4.Europe Genetic Testing Services Market-Key Industry Dynamics Figure 2.Europe Genetic Testing Services Market-Key Industry Dynamics Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 4.1 Key Market Drivers 4.1.1 Rising Pr

77、evalence of Genetic Diseases The prevalence of genetic diseases is rising across the world and impacting the health of people at a severe level.Genetic diseases show many symptoms that are uncommon and are mostly non-curable.Most of the genetic diseases are rare and are developed due to the mutation

78、 in the genetic makeup of the people.According to The World Health Organization(WHO)2021,10 out of every 1,000 people are affected by single-gene diseases,signifying that 70 million and 80 million people worldwide are living with any one type of single-gene disease.As per the Global Genes,7,000 know

79、n rare diseases and disorders have been identified worldwide,and more are being discovered every year.According to the University of Sheffield research,300 million people are living with genetic diseases around the world.In June 2020,as per Novartis AG(Switzerland)report,15,000 individuals were suff

80、ering from sickle cell disease in the UK,and 270 newborns are diagnosed with the condition every year.Thus,the rising prevalence of genetic diseases fuels the demand for genetic testing,which in turn drives genetic testing services market growth.DROTDRIVERSRESTRAINTSOPPORTUNITIESTRENDSRising Prevale

81、nce of Genetic DiseasesIncreasing Awareness and Acceptance of Personalized MedicinesGrowing Preference for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingAffordability of Genetic ServicesArtificial Intelligence-Powered Genetic TestingRising Demand for Pharmacogen

82、omics 21 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines Personalized medicine is the field that utilizes patients genetic and environmental data to deliver optimal healthcare.It is based on the principle that

83、 every patient is unique and requires individualistic pharmacological treatment.Since it is a rapidly evolving area,it is presently incorporated into several healthcare systems.The successful completion of the Human Genome Project(HGP)in 2003 and the fast-decreasing human genome sequencing costs enc

84、ouraged the development of a new medical approach,which is called personalized medicine.With an expanding repository of personalized data at the molecular level,molecular diagnostics companies are exceptionally positioned to unlock value.Large-scale drug discovery is a key to increasing the viabilit

85、y and usefulness of personalized medicines for the diagnosis of diseases and disorders.Genomics is one of the fastest-growing divisions of medical science.It is driving a paradigm shift in the research methodology of a disease,as well as diagnosing and treating illness.Genetic testing has been exten

86、sively used in pharmacogenomics,also known as drug-gene testing.It helps in accelerating drug discovery and its development.France also developed a national plan for personalized medicine known as Genomic Medicine France 2025.The program was presented to Prime Minister Manuel Valls by Yves Lvy,Presi

87、dent of the National Alliance for Life and Health SciencesAviesan and CEO of Inserm,in June 2016.It appeals to healthcare and manufacturing firms to pilot genomic sequencing platforms.The plan was supported by the government and launched with a public financing of US$760.8 million(670 million)in 202

88、0 for genomics and personalized medicine programs.It is expected to place France as a leader among countries involved in genomic medicine within the next ten years.In January 2023,The Human Genome Project is ensuring an era of personalized healthcare.Now,new research shows that precision prescribing

89、 using genetic testing has ultimately reached a global tipping point for adoption.Published by Cambridge University Press,the peer-reviewed research examines the maturation of critical factors required for the use of clinical genetics at scale.These advancements pave the way for supporting genome-in

90、formed clinical decision-making to be established as the new standard of care.Genetically informed prescribing offers one of the realistic mechanisms to successfully reduce the overall costs of the healthcare system and improve individual patient care.Genetic testing encourages the adoption of a per

91、sonalized medicine approach by understanding the science behind the disease,the impact of treatment,and the development of therapies for specific individual characteristics.It also helps healthcare personnel make informed decisions about disease diagnosis,treatment,and prevention by utilizing geneti

92、c testing results,leading to improved patient outcomes.4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing Personalized genetic testing and treatment have long been used globally to help individuals and families learn more about hereditary diseases.Most of the time,genetic testing is

93、 done through healthcare personnel,such as genetic counselors.Healthcare providers decide which test is needed,order the test from a test center,collect and send the DNA sample,read the test results,and share the results with the patient.Thus,these tests have traditionally been ordered and interpret

94、ed in a clinical or medical research setting.In contrast,DTC genetic testing has witnessed tremendous growth in the past decade and is becoming increasingly widespread.A genetic test offered,advertised,and sold by companies directly to the consumer,without the direct involvement of a conventional he

95、althcare system,is called DTC genetic testing.DTC genetic testing is relatively new and helps people find out about the disease-associated genes they may carry without the need for a prescription or guidance from a genetic counselor or medical practitioner.Several consumers of DTC testing view it as

96、 another method of gathering medical information about themselves.22 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Unlike other genetic tests performed in clinics or hospitals,the consumer independently initiates and completes a DTC genetic test.The public understanding and

97、acceptance of genetic testing is gradually increasing.Additionally,there is a rise in consumers seeking customized products and experiences for the identification and addressing of unique needs.The launch of innovative products and the increase in the adoption of DTC genetic testing kits have made g

98、enetic testing more accessible to people.These kits enable users to undergo personalized health management within the comfort of their homes.Key industry players are also developing DTC genetic tests and implementing special marketing efforts that positively impact sales of DTC tests.A rising number

99、 of manufacturers are providing direct-to-consumer genetic testing that covers various health conditions and traits.The increasing demand for direct-to-consumer genetic testing products to learn about the genetic makeup and assess the risk of developing hereditary conditions for early disease detect

100、ion or prevention drives the market.4.2 Market Restraints 4.2.1 Social and Ethical Implications of Genetic Testing Genetic testing is poised to play an important role in the practice of obstetrics and gynecology.Physicians are required to become familiar with the presently accessible collection of g

101、enetic tests and their limitations to guarantee patients the utmost quality of care.However,the knowledge of genetic risks can result in potential social and psychological consequences for the people undergoing such tests.Socially,knowledge from genetic tests may lead to stigmatization and judgment

102、within the community.Refusing to undergo genetic testing,as well as choosing to undergo genetic testing,can both lead to discrimination and stigmatization,depending on the prevalent public standards concerning acceptance and use of the technology.Privacy and security concerns also arise as the avail

103、ability and commercialization of personal genetic data can lead to unauthorized access or misuse of sensitive information.The storage of genetic testing data and registries of patients generates concern,given that the results can negatively impact the family members.In addition,lack of informed cons

104、ent can lead to adverse reactions,such as increased anxiety and unnecessary preventive measures during the disclosure of genetic test results.Lack of proper counseling regarding the information about genetic risk and choices regarding genetic testing and its management can cause potential psychologi

105、cal distress.Therefore,the reluctance of patients to prefer genetic testing due to the social and ethical stigma impedes market growth.4.2.2 Affordability of Genetic Services At present,genetic services are expensive and,therefore,not accessible to all.Genetic research is presently underrepresented

106、in health research;however,studies are being conducted to establish the feasibility of such services.Present inequalities in the affordability and feasibility of genetic services are a cause of concern for the WHO and other prominent international organizations that are centered around public health

107、 and development concerns.The cost of the test also increases if more than one test is needed or if multiple family members need to be tested to obtain a significant result.For newborn screening,costs differ as per the state.Several states cover part of the overall cost,although most charge a fee of

108、 US$30 to US$150 per infant.Various factors,including the type of test,the complexity of analysis,and laboratory processing fees,influence the cost of these tests.Thus,the high costs,along with its affordability in emerging economies,restrain the market growth.23 Europe Genetic Testing Services Mark

109、et,2020-2030 |The Insight Partners 4.3 Market Opportunities 4.3.1 Rising Demand for Pharmacogenomics Pharmacogenomics presents a lucrative opportunity within the genetic testing market,offering personalized insights into medication response based on an individuals genetic profile.By scrutinizing gen

110、etic variations influencing drug metabolism,pharmacogenomics testing empowers healthcare providers to customize medication selection and dosing,enhancing treatment efficacy while minimizing adverse reactions.The tailored approach not only improves patient outcomes but also enhances safety in medicat

111、ion management.With the rising focus on precision medicine,the demand for pharmacogenomic testing services spans diverse medical specialties such as cardiology,psychiatry,oncology,and primary care.Companies equipped with pharmacogenomic testing solutions,complemented by robust interpretation and rep

112、orting capabilities,stand poised to meet this demand.By supporting informed clinical decision-making and optimizing medication regimes,these companies play a pivotal role in advancing personalized healthcare and improving patient welfare across healthcare settings.4.4 Future Trends 4.4.1 Artificial

113、Intelligence-Powered Genetic Testing Whole-genome sequencing and now whole-exome sequencing have also become more popular.To solve the growing problem of health data exhaust,the field of medicine is increasingly revolving around enhanced clinical tools,such as artificial intelligence(AI)and machine

114、learning,which have been mentioned as a way to improve the acceptance of genomic medicine.Today,many companies have turned to machine learning to process the vast amount of data needed to correctly analyze and understand clinical data in fields such as radiology and cardiology.Many of the consumer-f

115、acing genetic testing technologies that are available in the market are using machine learning or AI to function.In numerous ways,genetic testing of diseases is the perfect field for machine learning because of the vast volumes of data that these programs need to struggle with.For example,working on

116、 the human genome includes reading billions of bits of information,and prior to the introduction of machine learning,many of these tasks were pretty tricky.AI offers great potential when it comes to analyzing genetic data and supporting clinical specialists in making diagnoses.Google has a program c

117、alled Deep Variant that can now be used to plot the human genome thoroughly and can be used on the full range of a persons genetic information.Moreover,agencies such as the National Institutes of Health are working on ways through which machine learning and AI can add to a better understanding of ge

118、netics and genomics.Furthermore,Blueprint Genetics is using AI in clinical interpretation.Machine learning and AI are acting as a catalyst for faster and more diverse improvement in genetic research and engineering.These tools are simple to integrate and extremely scalable,putting genetic laboratori

119、es in a unique position to scale their operations and match the fast growth of the genetic testing field.Thus,through the successful integration of these tools,clinicians will be able to diagnose rare genetic diseases more efficiently and effectively,bringing hope to the millions of people affected

120、by them globally.24 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 4.5 Impact Analysis:The following figure depicts the impact of factors driving and restraining the Europe genetic testing services market.The factors driving the market growth include increasing prevalence of

121、genetic diseases,increasing awareness and acceptance of personalized medicines,and growing preference for direct-to-consumer genetic testing.However,social and ethical implications of genetic testing and affordability of genetic services hinders the market growth.Figure 3.Impact Analysis of Drivers

122、and Restraints Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Rising Prevalence of Genetic DiseasesGrowing Preference towards for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingLOWMEDIUMHIGHIncreasing Awareness an

123、d Acceptance of Personalized Medicines 25 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 5.Genetic Testing Services Market-Europe Market Analysis European genetic testing services market is segmented into Germany,the UK,France,Italy,Spain,and the Rest of Europe.Genetic testin

124、g has been growing at an exceptional rate;a large panel of tests are now offered to screen a number of genetic diseases.Treatments are available for a number of rare genetic diseases,and the process is gaining importance in scenarios such as carrier testing,newborn screening,and predictive and pre-s

125、ymptomatic testing,among others.Moreover,European countries have undertaken a number of initiatives to increase awareness among people about the benefits of genetic testing.The ultimate goal is to ensure that all aspects of genetic testing are of high quality,thereby providing accurate and reliable

126、results for the benefit of the patients.5.1 Europe Genetic Testing Services Market Revenue(US$Mn),2022 2030 The Europe genetic testing services market is expected to reach US$2,778.42 million by 2030 from US$931.11 million in 2022.The market is estimated to grow at a CAGR of 14.6%from 2022 to 2030.T

127、he factors driving the market growth include the increasing prevalence of genetic diseases,growing preference for direct-to-consumer genetic testing,and increasing awareness and acceptance of personalized medicines.However,social and ethical implications of genetic testing and affordability of genet

128、ic services restrain the growth of the market.Figure 4.Europe Genetic Testing Services Market Revenue(US$Mn),2022 2030 Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 748.82834.61931.111,045.171,180.381,341.191,533.121,763.062,039.602,373.522,778.4211

129、.5%11.6%12.2%12.9%13.6%14.3%15.0%15.7%16.4%17.1%0.0%2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%18.0%2020202120222023202420252026202720282029203005001,0001,5002,0002,5003,0002020-2030Historical YearBase YearForecast Year 26 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.Europe Gene

130、tic Testing Services Market Revenue and Forecast to 2030 by Service Type 6.1 Overview The Europe genetic testing services market,by service type,is segmented into predictive testing,carrier testing,prenatal testing,newborn screening,and others.In 2022,the predictive testing segment held the largest

131、share of the market and is expected to register the highest CAGR in the market during the coming years.6.2 Europe Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Figure 5.Europe Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Source:The Insight Par

132、tners Analysis The predictive testing segment led the market in 2022 with a share of 38.9%and is expected to retain its dominance during 20222030 by accounting for 42.7%of the total market by 2030.38.9%23.8%13.0%15.2%9.1%2022Predictive TestingCarrier TestingPrenatal TestingNew-born ScreeningOthers42

133、.7%24.4%12.3%15.3%5.3%2030 27 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3 Predictive Testing 6.3.1 Overview Predictive genetic testing examines any genetic changes or mutations that are linked to disease.These tests are done prior to an individual displaying any signs

134、of a disease.Predictive testing can be helpful to people who have a family history of a treatable genetic disorder and display no signs of illness.This testing can identify mutations that increase an individuals risk of developing disorders with a genetic foundation,such as certain types of cancer.A

135、n example is testing for the BRCA1 and BRCA2 gene variants(altered genes)linked with an increased risk of breast cancer.The results of predictive testing can provide information about the probability of developing a specific disorder and help in making decisions about medical care.The increasing dem

136、and for genetic counseling is expected to drive the market for predictive testing as more people understand the importance of genetics in disease etiology.The ongoing advancements and upgrading of platforms to improve the efficiency of genome analysis techniques are expected to boost the adoption of

137、 predictive testing solutions.A growing focus on reducing the growing healthcare burden of rare genetic diseases and rapid integration of technologies such as artificial intelligence and machine learning will enhance product development and fuel the need for predictive testing to assess and prevent

138、future complications arising from diseases effectively.6.3.2 Predictive Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Predictive testing segment was valued at US$362.50 million in 2022 and is expected to reach US$1,185.45 million by 2030.The growth rate of th

139、is segment is projected to be 16.0%during 20222030.Figure 6.Predictive Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 284.59321.06362.50411.77470.53540.88625.44727.48851.121,001.571,185.

140、45202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 28 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.4 Carrier Testing 6.4.1 Overview Carrier testing is a kind of genetic test that can tell whether one carries a gene for certain gen

141、etic disorders or not.When it is done before or during pregnancy,it helps to find out the chances of having a child with a genetic disorder.Carrier testing is used to identify people carrying one copy of a gene mutation(a genetic change)that,when present in two copies,results in a genetic disorder.C

142、arriers generally do not have symptoms or have only mild symptoms.They often are unaware that they have a gene for a disorder.TaySachs disease is most common in Eastern or Central European Jewish people,French Canadian people,and Cajun descent.Although,anyone can have one of these disorders as they

143、are not restricted to these groups.With the increasing prevalence of genetic diseases caused by chromosome and gene mutations,carrier testing has grown exponentially.The majority of cases of genetic mutations are due to preexisting conditions,a family history of abortion,or congenital disabilities.P

144、regnant women often undergo carrier screening in order to determine the risk of transmitting a specific genetic disease to their progeny.In addition,the increasing recognition of the importance of early diagnosis and screening of gene illness fuels the need to develop strategies to tackle these dise

145、ases.6.4.2 Carrier Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Carrier testing segment was valued at US$221.43 million in 2022 and is expected to reach US$678.79 million by 2030.The growth rate of this segment is projected to be 15.0%during 20222030.Figure

146、7.Carrier Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 176.85197.80221.43249.41282.64322.24369.60426.46495.00577.96678.79202020212022202320242025202620272028202920302020-2030Historical

147、 YearBase YearForecast Year 29 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.5 Prenatal Testing 6.5.1 Overview Genetics can have an impact on the color of a babys eyes and hair and can also result in the development of some birth defects or genetic disorders.This testing h

148、elps to detect abnormalities in a fetuss genes or chromosomes and syndromes before birth.Thats why women are regularly offered a wide range of prenatal genetic testing in the first and second trimesters of pregnancy to evaluate the problems in their unborn babies.According to the WHO,congenital disa

149、bilities affect 8 million newborns every year.Nine out of every ten children are born with a serious birth defect in low-and middle-income countries.Congenital disabilities can occur at any point through the pregnancy;however,most of them occur during the first trimester when the babys organs are fo

150、rmed.With the ease of availability,pregnant females and their families are showing increased adoption toward the conduction of prenatal tests.According to the National Human Genome Research Institute(US),since December 2016,the adoption of prenatal genetic tests has notably increased with the introd

151、uction of noninvasive prenatal tests for the diagnosis of a range of genetic disorders in females.The segment is expected to show rapid growth in the coming years owing to the increasing prenatal testing and screening in developed regions such as North America and Europe and the new genetic tests in

152、troduced by the players in the market.For instance,in February 2019,Invitae Corporation,one of the leading genetics companies,introduced a noninvasive prenatal screening that offers in-depth genetic information about the child in early pregnancy.The company announced the launch in Las Vegas in conju

153、nction with the Society for Maternal-Fetal Medicine meeting.6.5.2 Prenatal Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Prenatal testing segment was valued at US$121.00 million in 2022 and is expected to reach US$342.00 million by 2030.The growth rate of thi

154、s segment is projected to be 13.9%during 20222030.Figure 8.Prenatal Testing:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 98.59109.17121.00134.92151.37170.84193.98221.56254.56294.20342.00202020

155、212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 30 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 6.6 Newborn Screening 6.6.1 Overview A newborn screening test looks for various developmental,genetic,and metabolic disease disorders in the

156、newborn.Newborn screening allows measures to be taken before symptoms develop.Most of these illnesses are extremely rare but can be treated if detected early.The offspring has a high risk of having genetic diseases in cases where the parents have another child with a genetic disease,a family history

157、 of a genetic disorder,or if either of a parent has a chromosomal abnormality.Early testing for these conditions allows physicians and parents to take timely measures to manage,treat,or intervene in disease progression,allowing the baby to lead a healthy,normal life.6.6.2 Newborn Screening:Europe Ge

158、netic Testing Services Market Revenue and Forecast to 2030(US$Million)Newborn screening segment was valued at US$141.37 million in 2022 and is expected to reach US$424.53 million by 2030.The growth rate of this segment is projected to be 14.7%during 20222030.Figure 9.Newborn Screening:Europe Genetic

159、 Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 113.51126.62141.37158.82179.50204.12233.52268.76311.16362.38424.53202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 31 E

160、urope Genetic Testing Services Market,2020-2030 |The Insight Partners 6.7 Others 6.7.1 Overview The others segment is comprised of preimplantation testing and pharmacogenomics.These tests are performed to screen for genetic disorders.Pharmacogenomics testing is a type of genetic test that is used to

161、 identify the right medication for a person.Pharmacogenomics is one of the key emerging trends in the field of medical science,which significantly impacts the drug development process.With the use of pharmacogenomics,target identification by drugs has become comparatively easy,which confirms much hi

162、gher chances of success for the approval of drugs.Currently,various ongoing initiatives of pharmacogenomics implementation have been launched in the US,Europe,and Asia.In the US,27 institutions are involved in programs that are applying pharmacogenomics,some of which have been using it for over ten

163、years.In 2007,a wide network of several associations was introduced with the creation of the Electronic Medical Records and Genomics(eMERGE)Network.Afterward,they started a study named eMERGE-PGx together with the Pharmacogenomics Research Network(PGRN),with the aim of testing genetic variation in 8

164、2 pharmacogenes through targeted sequencing.Moreover,since September 2010,with the Vanderbilt Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment program(PREDICT),more than 10,000 patients have undergone preemptive,panel-based pharmacogenomic testing.In 2011,PGRN also commenced the

165、 Translational Pharmacogenetics Program to assess PGx implementation in routine care by identifying barriers and developing solutions.Preimplantation genetic testing is also for couples who are at risk of having a child with a specific genetic or chromosome disorder,e.g.,cystic fibrosis or sickle ce

166、ll disease.In this procedure,egg cells are removed from the womans ovaries and fertilized with sperm cells outside the body.The fertilized embryos develop for three days,and subsequently,one or two cells are removed from each embryo.The genetic material(DNA and chromosomes)from the cells is tested f

167、or the genetic disorder in the family history.One or two of the unaltered embryos are then relocated into the mothers womb(uterus).If the pregnancy is successful,the baby will not be affected by the disorder it was tested for.6.7.2 Others:Europe Genetic Testing Services Market Revenue and Forecast t

168、o 2030(US$Million)Others segment was valued at US$84.80 million in 2022 and is expected to reach US$147.65 million by 2030.The growth rate of this segment is projected to be 7.2%during 20222030.32 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 10.Others:Europe Genetic

169、Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 75.2879.9684.8090.2596.33103.10110.59118.81127.77137.41147.65202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 33 Europe

170、Genetic Testing Services Market,2020-2030 |The Insight Partners 7.Europe Genetic Testing Services Market Revenue and Forecast to 2030 by Disease 7.1 Overview The Europe genetic testing services market,by disease,is segmented into cancer,cardiovascular diseases,metabolic diseases,and other diseases.I

171、n 2022,the cancer segment held the largest share of the market and is anticipated to grow at the highest CAGR during the coming years.7.2 Europe Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Figure 11.Europe Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)

172、Source:The Insight Partners Analysis The cancer segment led the market in 2022 with a share of 45.3%and is expected to retain its dominance during 20222030 by accounting for 49.0%of the total market by 2030.45.3%22.5%18.5%13.7%2022CancerCardiovascular DiseasesMetabolic DiseasesOther Diseases49.0%23.

173、1%17.7%10.2%2030 34 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 7.3 Cancer 7.3.1 Overview Genetic testing is a potential tool to identify individuals who are at higher risk for developing certain cancers because of family history.Genetic tests are available to examine inhe

174、rited variants and alterations in the DNA sequence,which could result in excessive cell growth and can cause tumors or cancer.For example,genetic testing for the detection of PALB2(linked with increased risks of breast and pancreatic cancers),BRIP1(ovarian cancer),RAD51C and RAD51D(ovarian cancer),a

175、nd CHEK2(breast and colorectal cancers).The worldwide growing prevalence of various cancers,such as breast,lung,and bowel,are the major drivers of this segment.According to the American Cancer Society,1,898,160 new cancer cases and 608,570 cancer deaths were anticipated to occur in the US in 2021.Ne

176、arly 10%to 20%of all cancers are related to gene mutations that are inherited or passed down through the family.Approximately 510%of cancers diagnosed in the US are associated with hereditary cancer syndromes.During the last decade,efforts have been made by the public health,medical,and scientific c

177、ommunity to update the public about ideas such as family history,hereditary cancer risk,and genetic testing for inherited cancer.For instance,CDCs Cancer Genomics Program develops best practices in education,surveillance,and policy and systems transformation approaches.It establishes an evidence bas

178、e for the application of family history and cancer genomics in public health practice.Other factors that might impact cancer genetic testing awareness include DTC marketing of cancer genetic testing and federal regulations of genetic information,high awareness regarding the availability of quality c

179、ancer diagnostics tests,and the escalating incidence of hereditary diseases.In addition,a growing number of companies providing genomic profiling services for health assessment,including cancer risk prediction,and the availability of numerous laboratories offering genetic testing for BRCA,and other

180、genes associated with hereditary breast,ovarian,and related cancers propel the market for the segment.7.3.2 Cancer:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cancer segment was valued at US$421.40 million in 2022 and is expected to reach US$1,362.63 million by 203

181、0.The growth rate of this segment is projected to be 15.8%during 20222030.Figure 12.Cancer:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 331.78373.76421.40477.98545.41626.07722.93839.69981.031,

182、152.861,362.63202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 35 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 7.4 Cardiovascular Diseases 7.4.1 Overview Heart diseases are a prominent cause of death worldwide and often run in famil

183、ies.In addition,as per the World Heart Federation 2023,rare cardiovascular diseases(CVD)are common,affecting 5%of the global population.There are over 6,000 known rare diseases,a handful of which impact the heart and circulatory system.And 83%of physicians agree that genetic testing is useful in fin

184、ding the diagnosis.Certain CVD conditions,such as cardiomyopathy,arrhythmia,and connective tissue disease,are caused by a single harmful DNA variation(or mutation).However,others,such as heart attack and high blood pressure,are usually caused by the combined effect of many smaller-impact DNA variati

185、ons.More than 1 in 200 people have an inherited form of CVD disease,but most are unaware of it.Patients with an inherited cardiovascular condition display few or no symptoms but still face significant risk of heart disease,including sudden cardiovascular arrest.Genetic testing can help save lives an

186、d is informative and useful for the clinical management and treatment of numerous inherited CVDs.7.4.2 Cardiovascular Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cardiovascular diseases segment was valued at US$209.74 million in 2022 and is expected to rea

187、ch US$643.07 million by 2030.The growth rate of this segment is projected to be 15.0%during 20222030.Figure 13.Cardiovascular Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 167.51187.35

188、209.74236.24267.72305.24350.11403.98468.92547.53643.07202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 36 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 7.5 Metabolic Diseases 7.5.1 Overview Diagnosis through genetic testing can stron

189、gly help discover the cause of persistent,often debilitating,undiagnosed signs in individuals suffering from suspected genetic metabolic disease disorders.With knowledge of variants in over 1,250 metabolic disease disorders genes,the rapid testing and experience of metabolic diseases can help to dia

190、gnose and manage the patients metabolic disease disorders quickly and correctly.Ultimately,this can provide new insights into treatment choices and the probability of passing the inherited condition on to the offspring or the presence of it elsewhere in the extended family.CentoICU is a comprehensiv

191、e next-generation sequencing panel that includes genes explicitly chosen for the genetic testing of extremely ill newborns and children under 24 months in intensive care units.In addition,Prevention Genetics offers a wide variety of genetic testing for inherited metabolic disease disorders,also know

192、n as inborn errors of metabolism.Panels specific to one disorder are available,as well as comprehensive metabolic diseases panels that cover broader phenotypic features or groups of similar disorders are also offered,including tests for hyperammonemia(37 genes),metabolic diseases hypoglycemia(38 gen

193、es),and metabolic diseases myopathies,rhabdomyolysis,and exercise intolerance(83 genes).Over the past year,the company has started to offer several new tests related to these metabolic disorders,and many of the existing panels have been updated to include more genes and increase clinical sensitivity

194、.7.5.2 Metabolic Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Metabolic diseases segment was valued at US$172.07 million in 2022 and is expected to reach US$490.56 million by 2030.The growth rate of this segment is projected to be 14.0%during 20222030.Figur

195、e 14.Metabolic Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 139.93155.10172.07192.07215.70243.70277.00316.73364.31421.51490.56202020212022202320242025202620272028202920302020-2030Hist

196、orical YearBase YearForecast Year 37 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 7.6 Other Diseases 7.6.1 Overview The others segment by disease comprises Duchenne Muscular Dystrophy(DMD),Thalassemia,Huntingtons Disease,and Fragile X Syndrome,among others.Genetic mutations

197、 that cause DMD fail to produce dystrophin protein.Recessive diseases caused by alterations in genes on the X chromosome include DMD and fragile X syndrome.Genetic testing is used to diagnose Duchenne,to access mutation-specific therapies,and for family planning.For Duchenne,the dystrophin gene is e

198、xamined to detect the presence of any changes or mutations that can inhibit the gene from working properly.Genetic testing is generally performed on a blood or saliva sample.A thalassemia is a group of inherited,genetic blood disorders that occur when the production of hemoglobin is disrupted.The di

199、sease is passed to children by parents carrying the mutated thalassemia gene.A kid who inherits one mutated gene is a carrier,and most carriers lead a completely normal and healthy life.At the same time,a child who inherits two thalassemia trait genes,i.e.,one from each parent,will have the disease.

200、A child of two carriers has a 25 percent chance of developing the disease and a 50 percent chance of being a carrier.Thus,in such cases,genetic testing is helpful in detecting and diagnosing thalassemia.Currently,two major approaches are used in DNA diagnosis and study of genetic disease,namely dire

201、ct tests and indirect tests(linkage analysis).Direct tests are being conducted for thalassemia and DMD.Carrier testing can be conducted for X-linked recessive disorders,such as DMD or fragile X syndrome.In these cases,the mother of an affected child with no other affected relatives may desire carrie

202、r testing to confirm whether the disease is a heritable trait or a new mutation.Many diseases may become apparent only in middle age or later.Predictive or presymptomatic testing and screening can provide symptoms that people may later develop these disorders.In some cases,a family history of a mono

203、genic disorder in a relative informs other members of the family that they are at high risk for developing the disease.Suitable genetic testing can help to resolve whether the mutant gene is present or not.Examples include Huntingtons disease.7.6.2 Other Diseases:Europe Genetic Testing Services Mark

204、et Revenue and Forecast to 2030(US$Million)Other diseases segment was valued at US$127.90 million in 2022 and is expected to reach US$282.16 million by 2030.The growth rate of this segment is projected to be 10.4%during 20222030.38 Europe Genetic Testing Services Market,2020-2030 |The Insight Partne

205、rs Figure 15.Other Diseases:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 109.60118.40127.90138.88151.54166.18183.09202.67225.34251.63282.16202020212022202320242025202620272028202920302020-2030

206、Historical YearBase YearForecast Year 39 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 8.Europe Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider 8.1 Overview The Europe genetic testing services market,by service provider,is segmented into hosp

207、ital-based laboratories,diagnostic laboratories,and others.In 2022,the hospital-based laboratories segment held the largest share of the market and is estimated to grow at the highest CAGR during 20222030.8.2 Europe Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Figure

208、 16.Europe Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Source:The Insight Partners Analysis The hospital-based laboratories segment led the market in 2022 with a share of 63.4%and is expected to retain its dominance during 20222030 by accounting for 68.5%of the tota

209、l market by 2030.63.4%25.9%10.7%2022Hospital-BasedLaboratoriesDiagnostic LaboratoriesOther End Users68.5%26.2%5.3%2030 40 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 8.3 Hospital-Based Laboratories 8.3.1 Overview Hospital-based laboratories are genetic testing service prov

210、iders that operate within a hospital setting.For extremely specialized tests,samples may go to a research laboratory.Nearly all hospitals contain a laboratory,which is commonly proportionate in size to the population it serves.The hospitals process hundreds of samples in very les time.Tests that are

211、 performed include those needed in emergencies,such as markers for heart attack and tests where results are required rapidly for patient care.They may also offer carrier testing to determine if an individual is carriers of certain genetic conditions that can be passed on to their children.Hospital l

212、aboratories can be segmented by type of testing and staffed by personnel trained in particular specialties.For instance,some sections can focus on microbiology,hematology,chemistry,and blood banking.At the same time,some units may perform highly specialized genetic tests using electron microscopy an

213、d immunohistochemistry,and others can focus on surgical pathology and cytology,which are all linked with the investigation of cell and tissue structure.The market growth for the segment can be due to the compulsory newborn screening for genetic disorders and the growing prevalence of cancer in many

214、regions.Seattle Childrens Hospital in Washington,Wyoming,Alaska,Montana,and Idaho(WWAMI)region provides comprehensive genetic testing and consultative services to healthcare workers and families.Their genetics laboratories consist of molecular genetics,cytogenetics,biochemical genetics,and a researc

215、h and development laboratory devoted to bringing the most existing and specific research tests into the clinical field.Overall,these laboratories play a crucial role in helping to diagnose genetic disorders,guide treatment decisions,and improve patient outcomes.8.3.2 Hospital-Based Laboratories:Euro

216、pe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Hospital-based laboratories segment was valued at US$590.51 million in 2022 and is expected to reach US$1,903.84 million by 2030.The growth rate of this segment is projected to be 15.8%during 20222030.Figure 17.Hospital-Based

217、 Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 465.37524.00590.51669.50763.63876.211,011.381,174.321,371.531,611.231,903.84202020212022202320242025202620272028202920302020-2030Hist

218、orical YearBase YearForecast Year 41 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 8.4 Diagnostic Laboratories 8.4.1 Overview Diagnostics laboratories are independent entities that provide all the diagnostic tests,screening tests,and others to the patient.These centers may b

219、e found attached to a private or public hospital.The tests performed in the diagnostic centers are obtained earlier than hospitals.The diagnostic centers also offer packages for whole-body check-ups that are cost-effective for the patients.Tests such as cell-free fetal DNA testing,triple or quadrupl

220、e screening tests,sequential screening,and others require advanced techniques,equipment,and skilled labor.However,some of the hospitals and clinics do not have all the required equipment and techniques for efficient diagnosis.Therefore,various hospitals and clinics prefer to outsource tests to diagn

221、ostics centers.The diagnostics centers are well equipped and offer better results for the tests performed for diseases and health conditions.The diagnostic centers provide multiple tests under one roof and offer all the prenatal diagnostics services such as screening,imaging,blood tests,chorionic vi

222、llus sampling,and amniocentesis.Thus,it becomes easier for people to undergo genetic testing in such facilities.The growing partnerships and collaboration of diagnostic laboratories with genetic testing companies and the rise in the incidences of genetic diseases across the world are anticipated to

223、offer growth to the market.For instance,Thermo Fisher Scientific allows laboratories to perform different genetic research and genetic testing by offering technologies such as NGS and quantitative PCR.8.4.2 Diagnostic Laboratories:Europe Genetic Testing Services Market Revenue and Forecast to 2030(U

224、S$Million)Diagnostic laboratories segment was valued at US$241.30 million in 2022 and is expected to reach US$727.00 million by 2030.The growth rate of this segment is projected to be 14.8%during 20222030.Figure 18.Diagnostic Laboratories:Europe Genetic Testing Services Market Revenue and Forecast t

225、o 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 193.60216.03241.30271.19306.64348.83399.23459.66532.39620.30727.00202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 42 Europe Genetic Testing Services Market,2020-2030

226、 |The Insight Partners 8.5 Others 8.5.1 Overview The others segment by service provider comprises academic and research institutions,pharmaceutical and biotechnology companies,and government agencies.Government agencies use genetic testing services to evaluate drugs for regulatory compliance for pub

227、lic health monitoring and research initiatives.Academic and research institutions are integral to the Europe genetic testing services market.They help in identifying genetic markers,developing new genetic testing methodologies,and improving existing tests.These institutions validate and ensure the q

228、uality of genetic tests through rigorous studies,establishing their reliability and credibility.Clinical trials and studies conducted by these institutions provide essential evidence on the clinical utility and effectiveness of genetic tests.Their expertise and research efforts advance the growth of

229、 the market,benefiting both patients and healthcare providers.In addition,research and academic institutes are among the leading users of genetic testing services.Academic institutes for medical sciences and biotechnology utilize analytical testing services to support their studies on drugs.Thus,the

230、 increasing demand for genetic testing services from government agencies and research institutes will likely continue to drive the Europe genetic testing services market for the segment.8.5.2 Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was val

231、ued at US$99.30 million in 2022 and is expected to reach US$147.59 million by 2030.The growth rate of this segment is projected to be 5.1%during 20222030.Figure 19.Others:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Inter

232、views,Secondary Sources 89.8594.5899.30104.48110.11116.15122.51129.09135.68141.99147.59202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 43 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.Europe Genetic Testing Services Market-Country

233、 Analysis 9.1 Europe Figure 20.Europe Genetic Testing Services Market,by Key Country Revenue,2022(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1 Europe Genetic Testing Services Market,by Country Figure 21.Europe Genetic Testing Servi

234、ces Market,By Key Countries,2022 and 2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources EUROPE(2022)152.3873.8495.32197.51196.79215.28Rest ofEuropeSpainItalyFranceUKGermany21.1%23.1%21.2%7.9%10.2%16.4%2022UKGermanyFranceSpainItalyRest of Europe22.

235、6%24.0%21.6%7.7%9.6%14.4%2030 44 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1 UK 9.1.1.1.1 Overview The UK genetic testing services market growth is attributed to the rise in the prevalence of genetic disorders and cancer.For instance,as per Genetic Alliance UK 2021

236、,rare diseases affect 3.5 million people in the country;that is 1 in 17 people.As per Gene People UK 2023,it is estimated that 1 in 25 children suffer from a genetic disorder,meaning that 30,000 babies and children are newly diagnosed yearly in the UK,and over 2.4 million children and adults are suf

237、fering from a genetic disorder.Various initiatives by the government further spur market growth.For instance,the UK Genetic Testing Network(UKGTN),an advisory organization in the UK,promotes equity of access to genetic testing and provides contracting support to the National Health Service(NHS).In a

238、ddition,Genetic Disorders UK has established a registered charity with an aim to improve the lives of people and families affected by genetic disorders.Moreover,the 100,000 Genomes Project launched by the UK government in 2012 is strengthening the NHSs position as one of the most advanced healthcare

239、 systems worldwide.In addition,the project is consolidating the foundation for personalized medicine,and this,in turn,contributes to the growth of genetic testing in the country.Great advances are being made in genomics,paving the way for enhanced access to personalized medicine.The country establis

240、hed the infrastructure to support greater access to genomic testing,including a national network of genomic laboratories and Genomic Medicine Centers that provide clinical services.These were established with the objective of embedding personalized medicine as part of routine clinical practice.In 20

241、19,the government announced Early Disease Detection Research Project UK,which is a significant new initiative that focuses on the major chronic diseases of adult life,including all cancers,cardiovascular disease,and other such diseases.9.1.1.1.2 UK Genetic Testing Services Market Revenue and Forecas

242、t to 2030(US$Mn)The UK genetic testing services market accounted for US$196.79 Mn in 2022 and it is expected to grow at a CAGR of 15.6%during the period 2022-2030,to reach US$629.10 Mn in 2030.Figure 22.UK Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners

243、 Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 155.44174.82196.79222.86253.92291.04335.58389.23454.13532.95629.10202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 45 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners

244、 9.1.1.1.3 UK Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 2.UK Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 59.61 68.02 77.66

245、89.19 103.03 119.72 139.90 164.44 194.38 231.09 276.28 17.2%Carrier Testing 36.96 41.59 46.85 53.09 60.52 69.41 80.08 92.93 108.49 127.40 150.47 15.7%Prenatal Testing 20.05 22.46 25.17 28.39 32.21 36.76 42.20 48.74 56.62 66.15 77.75 15.1%Newborn Screening 23.41 26.28 29.53 33.39 37.97 43.45 50.01 57

246、.90 67.43 78.99 93.08 15.4%Others 15.40 16.47 17.57 18.81 20.19 21.71 23.39 25.22 27.20 29.32 31.52 7.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the predictive testing segment was worth US$.66

247、million in 2022 and is projected to reach US$276.28 million by 2030;it is expected to grow at a CAGR of 17.2%from 2022 to 2030.9.1.1.1.4 UK Genetic Testing Services Market,by Disease,20202030(US$Million)Table 3.UK Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Dis

248、ease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 68.95 78.20 88.76 101.36 116.43 134.54 156.38 182.84 215.02 254.34 302.58 16.6%Cardiovascular Diseases 34.64 39.14 44.26 50.36 57.64 66.37 76.87 89.56 104.96 123.73 146.71 16.2%Metabolic Diseases 29.11 32.62 36.58 41.27

249、 46.85 53.50 61.45 71.00 82.52 96.48 113.44 15.2%Others 22.73 24.86 27.18 29.87 33.00 36.64 40.88 45.82 51.61 58.40 66.37 11.8%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the cancer segment was wo

250、rth US$88.76 million in 2022 and is projected to reach US$302.58 million by 2030;it is expected to grow at a CAGR of 16.6%from 2022 to 2030.9.1.1.1.5 UK Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 4.UK Genetic Testing Services Market,by Service Provider Revenue and

251、Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 96.89 110.10 125.21 143.24 164.85 190.83 222.21 260.26 306.60 363.27 432.88 16.8%Diagnostic Laboratories 40.70 45.87 51.74 58.72 67.03 76.99 88.95 103.39 120.

252、87 142.13 168.11 15.9%Others 17.85 18.85 19.84 20.90 22.03 23.21 24.41 25.58 26.66 27.55 28.11 4.5%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 46 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners The Europe genetic testing

253、 services market for the hospital-based laboratories segment was worth US$125.21 million in 2022 and is projected to reach US$432.88 million by 2030;it is expected to grow at a CAGR of 16.8%from 2022 to 2030.9.1.1.2 Germany 9.1.1.2.1 Overview Medical genetics has become a vital part of clinical prac

254、tice.It has provided doctors with a valued diagnostic and an analytical pre-symptomatic tool,which they can use more effectively to manage patients diseases and even take preventive actions.As per a study titled Awareness and Knowledge of Rare Diseases in German Dentists,Dental Specialists,and Oral

255、and Maxillofacial Surgeons,published in 2022,rare diseases affect about four million patients in the country.Moreover,the rising prevalence of rare diseases and the development of custom-made testing kits for niche therapeutic areas,along with the adoption of genetic testing kits,are aiding the rapi

256、d growth of the market.As per Globocan 2020,69,697 new breast cancer cases were reported in 2020 in Germany,representing 11.1%of all registered cancer cases.It caused 20,579 fatalities,and the five-year prevalence rate of breast cancer in all ages was 707.38 per 100,000 population.Nearly 16%of women

257、 with triple-negative breast cancer carry a BRCA mutation in Germany.In 2018,the government of the country announced a strategy to include BRCA genetic testing in Germanys national cancer plan,which was initiated in 2008 with the goal of ensuring women with high genetic risk of breast cancer are leg

258、ally entitled to intensified screening and risk-reducing options.The increasing focus by the government to regulate and create awareness regarding genetic tests has effectively resulted in the faster adoption of tests across the country.In Germany,noninvasive prenatal testing became available as a p

259、ublicly reimbursed test in 2022.In addition,the introduction of reimbursement programs,increasing demand for efficient treatment options,and implementation of innovative technologies in research centers are expected to drive market expansion in the country.Growing awareness about the advantages of g

260、enetic testing,knowledge among healthcare professionals,and the rise in consumer spending on healthcare propels the market.9.1.1.2.2 Germany:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Germany genetic testing services market accounted for US$215.28 Mn in 2022 and it is

261、expected to grow at a CAGR of 15.2%during the period 2022-2030,to reach US$668.15 Mn in 2030.47 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 23.Germany:Europe Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Prim

262、ary Interviews,Magazines and Journals,Secondary Sources 9.1.1.2.3 Germany:Europe Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 5.Germany:Europe Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 20

263、25 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 63.13 71.59 81.25 92.75 106.52 123.06 143.00 167.15 196.51 232.36 276.34 16.5%Carrier Testing 39.16 44.16 49.85 56.61 64.68 74.34 85.96 99.99 116.99 137.68 162.99 16.0%Prenatal Testing 23.25 25.81 28.68 32.06 36.06 40.80 46.44 53.17 61.22

264、70.91 82.61 14.1%Newborn Screening 26.61 29.94 33.71 38.19 43.52 49.90 57.56 66.80 77.97 91.55 108.12 15.7%Others 19.25 20.50 21.79 23.24 24.86 26.64 28.61 30.75 33.06 35.52 38.08 7.2%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe gene

265、tic testing services market for the predictive testing segment was worth US$81.25 million in 2022 and is projected to reach US$276.34 million by 2030;it is expected to grow at a CAGR of 16.5%from 2022 to 2030.171.40192.00215.28242.86275.65314.75361.58417.85485.75568.03668.152020202120222023202420252

266、02620272028202920302020-2030Historical YearBase YearForecast Year 48 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2.4 Germany:Europe Genetic Testing Services Market,by Disease,20202030(US$Million)Table 6.Germany:Europe Genetic Testing Services Market,by Disease Revenu

267、e and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 76.02 86.16 97.73 111.52 128.02 147.83 171.71 200.62 235.76 278.66 331.27 16.5%Cardiovascular Diseases 38.59 43.29 48.62 54.92 62.43 71.39 82.13 95.05 110.66 129.59 152.65 15.4%Metab

268、olic Diseases 32.09 35.75 39.86 44.72 50.47 57.30 65.44 75.19 86.91 101.04 118.15 14.6%Others 24.69 26.79 29.07 31.70 34.73 38.24 42.29 46.99 52.43 58.75 66.09 10.8%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing service

269、s market for the cancer segment was worth US$97.73 million in 2022 and is projected to reach US$331.27 million by 2030;it is expected to grow at a CAGR of 16.5%from 2022 to 2030.9.1.1.2.5 Germany:Europe Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 7.Germany:Europe Ge

270、netic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 106.83 121.05 137.27 156.60 179.73 207.49 240.95 281.46 330.69 390.79 464.47 16.5%Diagnostic Lab

271、oratories 44.44 49.73 55.70 62.77 71.17 81.19 93.17 107.56 124.90 145.91 171.45 15.1%Others 20.13 21.22 22.31 23.48 24.74 26.08 27.45 28.83 30.16 31.33 32.23 4.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services m

272、arket for the hospital-based laboratories segment was worth US$137.27 million in 2022 and is projected to reach US$464.47 million by 2030;it is expected to grow at a CAGR of 16.5%from 2022 to 2030.49 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3 France 9.1.1.3.1 Over

273、view As per Globocan 2020 data,France recorded 58,083 new breast cancer cases,representing 12.4%of all registered cases.The five-year prevalence rate for breast cancer in all ages was 702.58 per 100,000 population.It was also the major cause of cancer deaths in women,causing 14,183 deaths in 2020 in

274、 the country.It is estimated that 2 in 1,000 women carry a BRCA1 or BRCA2 mutation.A woman in France has a lifetime risk of breast cancer of 5175%if she carries a BRCA1 mutation and 3355%if she has a BRCA2 mutation,compared with 12%for the general population.Additionally,as per the study titled RaDi

275、Co,the French national research program on rare disease cohorts,published in 2021,rare diseases affect 3 million people in the country.The country developed a national plan for personalized medicine,namely Genomic Medicine France 2025,which was announced in 2016 and is overseen and supported by the

276、State.The program appeals to healthcare and manufacturing firms to pilot genomic sequencing platforms.By 2020,the aim was to establish a network of centers able to process nearly 235,000 samples for whole genome sequencing.This ambitious plan aimed at positioning the country as a leader among the ma

277、jor countries involved in genomic medicine within the next ten years.In addition,France has well-developed policies and strategies in place for improving the prevention of hereditary cancers and other genetic diseases.For instance,BRCA-France is also involved in public support,aiming to expand genet

278、ic testing criteria.The organization is also calling for genetic testing criteria to be expanded to include the 8,00010,000 women in France with metastatic breast cancer.Similarly,the national neonatal screening program concerns all newborns in the country.It focuses on detecting rare,severe,and mos

279、t often genetic diseases on a collected blood sample.In 2020,the newborn screening program detected 557 major sickle cell syndromes,98 congenital hypothyroidism,93 hyperphenylalaninemia,37 congenital adrenal hyperplasia,and 122 cystic fibrosis.Thus,the factors mentioned above significantly support t

280、he growth of the market in the country.9.1.1.3.2 France Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)France genetic testing services market accounted for US$197.51 Mn in 2022 and it is expected to grow at a CAGR of 14.9%during the period 2022-2030,to reach US$600.13 Mn in 2030.

281、50 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 24.France Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1.3.3 France Genetic Testing Services Mar

282、ket,by Service Type,20202030(US$Million)Table 8.France Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 62.21 70.30 79.51 90.46 103.53 119.21 138.06 160.85 188.

283、49 222.16 263.37 16.2%Carrier Testing 38.51 43.11 48.31 54.47 61.80 70.53 80.98 93.54 108.70 127.05 149.38 15.2%Prenatal Testing 19.75 21.89 24.28 27.10 30.44 34.38 39.08 44.67 51.37 59.42 69.13 14.0%Newborn Screening 23.09 25.79 28.84 32.45 36.73 41.83 47.92 55.23 64.04 74.70 87.63 14.9%Others 14.5

284、7 15.55 16.57 17.73 19.03 20.50 22.14 23.96 25.98 28.20 30.61 8.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the predictive testing segment was worth US$79.51 million in 2022 and is projected to

285、reach US$263.37 million by 2030;it is expected to grow at a CAGR of 16.2%from 2022 to 2030.158.12176.64197.51222.21251.53286.45328.18378.26438.57511.52600.13202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 51 Europe Genetic Testing Services Market,2020-2030

286、|The Insight Partners 9.1.1.3.4 France Genetic Testing Services Market,by Disease,20202030(US$Million)Table 9.France Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 69.96 79.00 89.2

287、9 101.53 116.13 133.63 154.69 180.11 210.95 248.50 294.44 16.1%Cardiovascular Diseases 35.18 39.45 44.28 50.00 56.81 64.94 74.68 86.39 100.54 117.69 138.58 15.3%Metabolic Diseases 30.20 33.48 37.15 41.48 46.58 52.63 59.82 68.40 78.67 91.01 105.90 14.0%Others 22.78 24.70 26.79 29.21 32.00 35.24 38.99

288、 43.35 48.42 54.32 61.21 10.9%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the cancer segment was worth US$89.29 million in 2022 and is projected to reach US$294.44 million by 2030;it is expected t

289、o grow at a CAGR of 16.1%from 2022 to 2030.9.1.1.3.5 France Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 10.France Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 202

290、8 2029 2030 CAGR(20222030)Hospital-Based Laboratories 97.73 110.19 124.34 141.16 161.22 185.24 214.11 248.94 291.14 342.50 405.26 15.9%Diagnostic Laboratories 41.43 46.43 52.07 58.75 66.70 76.19 87.55 101.21 117.69 137.67 161.99 15.2%Others 18.95 20.02 21.10 22.30 23.60 25.01 26.52 28.11 29.74 31.35

291、 32.88 5.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the hospital-based laboratories segment was worth US$124.34 million in 2022 and is projected to reach US$405.26 million by 2030;it is expecte

292、d to grow at a CAGR of 15.9%from 2022 to 2030.52 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.4 Italy 9.1.1.4.1 Overview The increasing investments and rising funds dedicated to manufacturing companies,as well as academic and research institutes for the development of

293、 gene synthesis-based end products,such as precision medicine and other therapeutics,are the key factors fueling the market growth.In Italy,the approval of genetic and genomics applications for funding by the National Healthcare System is mostly unregulated.For this reason,the National Plan for Publ

294、ic Health Genomics proposed the development of a more comprehensive evaluation framework for genetic and genomic applications.Also,Italy was the first country in Europe to develop a plan and structure for Public Health Genomics.It also has guidelines on medical genetics and a national strategy to su

295、pport people with rare diseases.These factors significantly boost the growth of the market in Italy.As per UniCamillusSaint Camillus International University of Health and Medical Sciences data,there are 500 Down syndrome newborns annually in Italy,and 38,000 people are affected with Down syndrome.T

296、he number of centers providing genetic testing for such conditions in Italy is growing due to the increasing demand for genetic tests.Moreover,various organizations work toward raising awareness about genetic testing in the country.Salute Donna Onlus is an association engaged in several awareness-ra

297、ising and encouragement initiatives,including organizing a conference and supporting the Italian Senate to increase access to genetic testing across the country.9.1.1.4.2 Italy Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Italy genetic testing services market accounted for US$9

298、5.32 Mn in 2022 and it is expected to grow at a CAGR of 13.8%during the period 2022-2030,to reach US$267.99 Mn in 2030.Figure 25.Italy Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 7

299、7.7786.0695.32106.22119.09134.32152.41173.97199.74230.69267.99202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 53 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.4.3 Italy Genetic Testing Services Market,by Service Type,20202030(

300、US$Million)Table 11.Italy Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 28.64 31.98 35.74 40.18 45.44 51.70 59.17 68.12 78.88 91.87 107.61 14.8%Carrier Testi

301、ng 18.13 20.16 22.43 25.10 28.27 32.03 36.50 41.85 48.26 55.98 65.32 14.3%Prenatal Testing 11.09 12.24 13.53 15.05 16.84 18.95 21.46 24.44 28.01 32.28 37.42 13.6%Newborn Screening 12.21 13.51 14.96 16.67 18.68 21.07 23.90 27.28 31.32 36.17 42.01 13.8%Others 7.70 8.17 8.67 9.22 9.86 10.57 11.37 12.27

302、 13.28 14.40 15.63 7.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the predictive testing segment was worth US$35.74 million in 2022 and is projected to reach US$107.61 million by 2030;it is expec

303、ted to grow at a CAGR of 14.8%from 2022 to 2030.9.1.1.4.4 Italy Genetic Testing Services Market,by Disease,20202030(US$Million)Table 12.Italy Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(2022203

304、0)Cancer 34.49 38.61 43.27 48.78 55.31 63.10 72.39 83.55 96.97 113.21 132.92 15.1%Cardiovascular Diseases 17.52 19.47 21.66 24.24 27.30 30.93 35.25 40.40 46.59 54.04 63.04 14.3%Metabolic Diseases 13.57 14.96 16.51 18.34 20.48 23.02 26.03 29.60 33.87 38.97 45.11 13.4%Others 12.20 13.01 13.88 14.86 15

305、.99 17.28 18.74 20.41 22.31 24.46 26.91 8.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the cancer segment was worth US$43.27 million in 2022 and is projected to reach US$132.92 million by 2030;it

306、 is expected to grow at a CAGR of 15.1%from 2022 to 2030.9.1.1.4.5 Italy Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 13.Italy Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2

307、026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 48.46 54.13 60.51 68.06 77.00 87.63 100.32 115.52 133.80 155.88 182.65 14.8%Diagnostic Laboratories 18.80 20.78 22.99 25.59 28.66 32.29 36.59 41.72 47.85 55.19 64.04 13.7%Others 10.50 11.15 11.81 12.58 13.44 14.41 15.50 16.73 18.09 19

308、.61 21.29 7.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 54 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners The Europe genetic testing services market for the hospital-based laboratories segment was worth US$60.51 milli

309、on in 2022 and is projected to reach US$182.65 million by 2030;it is expected to grow at a CAGR of 14.8%from 2022 to 2030.9.1.1.5 Spain 9.1.1.5.1 Overview According to the Global Cancer Observatory 2020,34,088 new breast cancer cases were registered in the country,representing 12.1%of all new cancer

310、 cases.The five-year prevalence rate for breast cancer cases among all age groups was 577.34 per 100,000 population.According to the Spanish Network of Cancer Registries,the incidence of breast cancer in females was 34,750 in November 2022,with an increase of 0.9%yearly.Breast cancer patients have a

311、t least one hereditary risk cancer,which requires genetic counseling.Thus,the rising incidences of breast cancer are likely to propel the growth of the market.According to the article Myths and Truths about Down Syndrome,published in 2021,34,000 individuals with Down syndrome reside in Spain.As per

312、WCRF International and Globocan,40,441 new colorectal cancer cases were diagnosed in 2020 in Spain in both genders,including 24,610 colorectal cancer incidences among males and 15,831 in females.Genetic testing can be utilized in such conditions to check the probability of a person acquiring them in

313、 the future and get treatment accordingly.The presence of well-established companies in the country is further going to propel the growth.For instance,LabGenetics specializes in prenatal genetic testing and collaborates with public and private hospitals,clinics,and centers,both in Spain and globally

314、.Also,NIMGenetics is a privately owned Spanish biomedical company specializing in the design and commercialization of products and services for clinical genetic diagnosis.9.1.1.5.2 Spain Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Spain genetic testing services market accounte

315、d for US$73.84 Mn in 2022 and it is expected to grow at a CAGR of 14.1%during the period 2022-2030,to reach US$212.72 Mn in 2030.Figure 26.Spain Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary

316、 Sources 59.8966.4773.8482.5292.79104.98119.48136.79157.55182.53212.72202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 55 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.5.3 Spain Genetic Testing Services Market,by Service Type,2

317、0202030(US$Million)Table 14.Spain Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 23.19 26.04 29.26 33.07 37.61 43.03 49.51 57.31 66.72 78.13 92.01 15.4%Carrie

318、r Testing 14.36 15.99 17.82 19.98 22.54 25.58 29.21 33.56 38.77 45.06 52.69 14.5%Prenatal Testing 7.64 8.41 9.27 10.27 11.46 12.85 14.51 16.47 18.80 21.60 24.95 13.2%Newborn Screening 8.88 9.87 10.98 12.28 13.83 15.66 17.84 20.45 23.58 27.35 31.90 14.3%Others 5.82 6.16 6.51 6.91 7.36 7.86 8.41 9.02

319、9.68 10.40 11.17 7.0%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the predictive testing segment was worth US$29.26 million in 2022 and is projected to reach US$92.01 million by 2030;it is expected

320、 to grow at a CAGR of 15.4%from 2022 to 2030.9.1.1.5.4 Spain Genetic Testing Services Market,by Disease,20202030(US$Million)Table 15.Spain Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)C

321、ancer 26.51 29.75 33.41 37.75 42.91 49.06 56.42 65.27 75.95 88.89 104.64 15.3%Cardiovascular Diseases 13.37 14.88 16.58 18.59 20.97 23.80 27.17 31.21 36.06 41.91 48.99 14.5%Metabolic Diseases 11.38 12.54 13.83 15.35 17.14 19.24 21.74 24.71 28.24 32.47 37.56 13.3%Others 8.63 9.29 10.00 10.83 11.78 12

322、.87 14.14 15.60 17.30 19.26 21.53 10.1%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The Europe genetic testing services market for the cancer segment was worth US$33.41 million in 2022 and is projected to reach US$104.64 million by 2030;it is e

323、xpected to grow at a CAGR of 15.3%from 2022 to 2030.9.1.1.5.5 Spain Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 16.Spain Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2

324、027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 37.10 41.57 46.63 52.62 59.73 68.22 78.37 90.56 105.26 123.06 144.70 15.2%Diagnostic Laboratories 15.65 17.41 19.37 21.70 24.45 27.71 31.60 36.25 41.84 48.57 56.71 14.4%Others 7.14 7.49 7.83 8.20 8.61 9.05 9.51 9.98 10.46 10.91 11.31 4.7%S

325、ource:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 56 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners The Europe genetic testing services market for the hospital-based laboratories segment was worth US$46.63 million in 2022 and

326、is projected to reach US$144.70 million by 2030;it is expected to grow at a CAGR of 15.2%from 2022 to 2030.9.1.1.6 Rest of Europe 9.1.1.6.1 Overview The Europe genetic testing services market in the Rest of Europe is segmented into Poland,Austria,Switzerland,Sweden,Norway,Denmark,Belgium,and the Net

327、herlands.According to the Spanish Network of Cancer Registries,11,734 breast cancer cases were diagnosed in November 2022 in Belgium.Breast cancer was responsible for 2,362 deaths in the country in the same year.As per the same source,24,644 breast cancer cases were registered in 2020.In Poland,it c

328、aused 8,805 breast cancer-related deaths.The increasing technological advancements and growing product launches have opened up numerous market expansion opportunities for the companies.For instance,Estonian scientists invented a genetic testing technology in 2018 named the Endometrial Receptivity Te

329、st that grants the number of clinical biomarkers to be analyzed at the single-molecule level.In February 2022,Eurofins Clinical Testing Lux Sarl(Eurofins Scientifics subsidiary)acquired Genetic Testing Service JSC.Through the acquisition,the company aimed to expand its network and strengthen its glo

330、bal network of clinical diagnostic laboratories,which mostly focus on specialized and advanced genetic testing.In September 2022,Eurofins Genoma(part of the Eurofins),one of the most advanced European molecular diagnostics laboratories,introduced niPGTa noninvasive preimplantation genetic aneuploidy

331、 screening test.Preimplantation genetic testing for aneuploidy plays a crucial role in assisted reproductive technology applications.Therefore,the growing incidents of breast cancer and the launch of innovative products by the market players favor the market growth.9.1.1.6.2 Rest of Europe Genetic T

332、esting Services Market Revenue and Forecast to 2030(US$Mn)The Rest of Europe genetic testing services market accounted for US$152.38 Mn in 2022 and it is expected to grow at a CAGR of 12.8%during the period 2022-2030,to reach US$400.33 Mn in 2030.Figure 27.Rest of Europe Genetic Testing Services Mar

333、ket Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 126.21138.63152.38168.49187.40209.65235.90266.97303.86347.80400.33202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 57 Europe Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.6.3 Rest of Europe Genetic